In HER2-positive (HER2+) breast cancer, neoadjuvant chemotherapy (NAC) combined with anti-HER2 therapy can achieve high rates of pathological complete response (pCR), supporting the de-escalation of axillary surgery. This evidence concerns the gene ERBB2 and breast cancer.